OR52N5

Across TCGA pan-cancer cohorts, OR52N5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OR52N5 data layer compared with 15 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher OR52N5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR52N5 expression acts as an unfavorable survival marker.

BLCA, LIHC, and UCEC are the cancer types where OR52N5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	0.025	0.572	<.001	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	IV	0.040	0.432	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

OR52N5–BLCA (DFS)

Open the BLCA breakdown →